Photocure renegotiates HexVix licence: GE out, Ipsen in
This article was originally published in Clinica
Executive Summary
Photocure has put together a new commercial strategy for HexVix (hexaminolevulinate hydrochloride), its flagship product which helps in the diagnosis and resection of bladder cancer.
You may also be interested in...
Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted
The latest drug development news and highlights from our US FDA Performance Tracker.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.